GlassScriptPhysician profile
Yugandhar Munnangi
NPI 1316913932
$259,122.99
in general payments reported to CMS, 2019-2025
22 companies · $45K in 2025
The $45K reported for 2025 was more than what 98% of Psychiatry providers received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $26K · 2020: $16K · 2021: $22K · 2022: $35K · 2023: $58K · 2024: $57K · 2025: $45K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $137K · Food and Beverage: $13K · Travel and Lodging: $9,837 · Consulting Fee: $460 · Education: $218.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $136,588.96 |
| Food and Beverage | $13,430.24 |
| Travel and Lodging | $9,836.96 |
| Consulting Fee | $460.00 |
| Education | $218.43 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teva Pharmaceuticals USA, INC. | $86,417.32 | 2019-2025 | Austedo Xr, Austedo Xr, Austedo |
| Janssen Pharmaceuticals, INC | $84,267.40 | 2019-2025 | Invega Sustenna, Invega Trinza, Spravato |
| Otsuka America Pharmaceutical, INC. | $65,309.04 | 2019-2025 | Abilify Maintena, Abilify Asimtufii, Rexulti |
| Abbvie INC. | $12,416.85 | 2021-2025 | |
| Neurocrine Biosciences, INC. | $3,376.57 | 2019-2025 | Ingrezza |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $2,363.08 | 2020-2025 | Caplyta |
| Alkermes, INC. | $1,488.79 | 2019-2025 | Lybalvi, Aristada, Vivitrol |
| Axsome Therapeutics, INC. | $581.57 | 2023-2025 | Auvelity |
| Vanda Pharmaceuticals INC. | $542.69 | 2019-2025 | Fanapt, Hetlioz |
| Allergan, INC. | $530.30 | 2019-2020 | |
| E.R. Squibb & Sons, L.L.C. | $402.27 | 2024-2025 | Cobenfy |
| Sunovion Pharmaceuticals INC. | $344.90 | 2019-2022 | |
| Avanir Pharmaceuticals, INC. | $208.88 | 2020-2022 | |
| Eisai INC. | $167.30 | 2021 | |
| Indivior INC. | $154.53 | 2021-2024 | Perseris |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Braeburn INC. | $125.00 | 2024 | Brixadi |
| Biohaven Pharmaceutical Holding Company LTD. | $125.00 | 2022 | |
| Idorsia Pharmaceuticals US INC | $119.42 | 2022 | |
| Lundbeck LLC | $90.17 | 2019-2023 | Rexulti |
| Almatica Pharma LLC | $44.00 | 2021-2025 | Loreev Xr |
| Luye Pharma (USA) LTD. | $33.99 | 2025 | Erzofri Extended-Release |
| Alfasigma USA, INC. | $13.92 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Yugandhar Munnangi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.